Vanguard Portfolio Management
PLX icon

Vanguard Portfolio Management’s Protalix BioTherapeutics PLX Stock Holding History

Vanguard Portfolio Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Buy
510,639
+78,154
+18% +$166K ﹤0.01% 2908
2026
Q1 		$938K Buy
+432,485
New +$1.07M ﹤0.01% 2813

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Portfolio Management's PLX Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Protalix BioTherapeutics (PLX) stake by 18% in Q2 2026, buying an estimated $166K and bringing the position to 510,639 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2908.

Vanguard Portfolio Management first reported a position in PLX in Q1 2026 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Vanguard Portfolio Management held 510,639 shares of Protalix BioTherapeutics worth $1.19M as of Q2 2026.
  • Vanguard Portfolio Management bought 78,154 Protalix BioTherapeutics shares in Q2 2026, an estimated $166K.
  • Protalix BioTherapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2908 holding.
  • Vanguard Portfolio Management first reported a position in Protalix BioTherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.